Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Construction company Q-gruppen and Caverion continue their partnership – next project at Barkaby Station in Stockholm

Caverion Corporation Press release 23 May 2022 at 11.00 a.m. EESTConstruction company Q-gruppen and Caverion continue their partnership – next project at Barkaby Station in Stockholm Caverion and construction company Q-gruppen have signed an agreement for the construction of the Barkarby Station “Northern Entrance” in Stockholm, Sweden. Caverion is responsible for the technical installation of automation, security, electricity and information and telecommunications solutions in the project, which runs from May 2022 to November 2025. The end customer is the Swedish Transport

Riksbank launches service for instant payments

Today the RIX-INST service is launched, which means that payments between banks can be made in real time 24 hours a day and 365 days a year in central bank money. The Riksbank is thus offering the banks a secure and cost-effective payment system for instant payments that creates opportunities for Swedish companies to develop new innovative payment services. The service is connected to the Eurosystem payment platform, TIPS.Instant payments, when bank customers move money from one bank to another in just seconds, are becoming increasingly common. Sweden is already one of the world’s most

Ilya Pharma extends global patent coverage for ILP100 for the treatment of diseases of skin and mucosa in humans and animals

Low manufacturing costs, excellent temperature stability and high efficacy attracting increasing attentionUppsala, May 23, 2022: Ilya Pharma (the Company), a clinical stage immunotherapy company today announced that the Indian Patent Office (IPO) has issued the Company Patent No 395551 titled “Methods for Wound Healing”. The patent covers the general use of a plasmid capable of expressing the protein CXCL12 in L. reuteri. The modified bacteria may be used for treatment of both mucosal and cutaneous wounds in humans and animals. These claims protect inventions which are central to the

BLAST and Dansk Industri team up to support growth of esports industry in Denmark

Esports entertainment company BLAST and Dansk Industri (DI) will team up to support the long-term development of esports and establish a unified voice for the industry in Denmark.BLAST and DI will work together to help shape and support a framework to develop and further cement Denmark’s status as a leader in esports, an industry that is now valued at over a billion dollars and is on course to have a global esports viewership of 577 million by 2024.  Denmark has an illustrious history in esports, and has grown to become one of the most dominant esports nations in the world. The country

BioStock Studio: An in-depth look at Ultimovacs' cancer vaccine

The field of immuno-oncology is growing, and cancer vaccines are a big part of that. Norwegian biotech Ultimovacs is developing its own cancer vaccine technology platform. BioStock invited Sara Mangsbo, Chief Innovation Officer at Ultimovacs, to the Studio to learn more.Watch the interview with Sara Mangsbo at biostock.se : https://www.biostock.se/en/2022/05/an-in-depth-look-at-ultimovacs-cancer-vaccine/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

SmartCraft ASA (SMCRT) - Invitation to presentation of first quarter 2022 results

SmartCraft ASA | Non-regulatory press releases 23 May 2022 – SmartCraft ASA will publish its first quarter 2022 financial report on Tuesday 24 May 2022 at 07:00 CET together with the Q1 2022 presentation material on the company website and www.newsweb.no. Investors, analysts, and journalists are welcome to join to an English language webcast presentation of the report on the same day, Tuesday 24 May 2022, at 08:00 CET. Webcast link:https://channel.royalcast.com/landingpage/hegnarmedia/20220524_1/ Presenters: Chief Executive Officer Gustav Line, Chief Financial Officer Kjartan

BioStock: Aptahem signs agreement with CRO for phase I studies

Aptahem has entered into an agreement with a clinical contract research organisation in the Netherlands for the implementation of the upcoming phase I sepsis study with the drug candidate Apta-1. The news followed the earlier announcement that Aptahem has joined a new research consortium that will evaluate novel treatments to reduce inflammation in cardiovascular diseases and breast cancer, again focusing on Apta-1.Read the full article at biostock.se: https://www.biostock.se/en/2022/05/aptahem-signs-agreement-with-cro-for-phase-i-studies/ This is a press release from BioStock -

9 Trees, 1 Aim for Chelsea Flower Show.

9trees to help RHS members balance their carbon footprint.Chelsea, London. Monday 23rd May 2022. For immediate release. Powys based 9Trees is honoured to be a guest of Harrison Ovens who’s stand at this year’s RHS Chelsea Flower Show has been designed by award-winning designer Sarah Morgan founder of The Garden Creative Featuring three native trees Birch, Hazel & Elder (Betula Pendula, Crataegus Monogyna and Sambucus Nigra). 9Trees usually plants up to 15 different types of trees in their new woodlands. Creating a rich diversity for wildlife and wellbeing, not profit. One of

Loughton Contracts saves £250,000 a year with Medius’s accounts payable technology

UK’s leading flooring contractor introduced automated payments for 2,000-3,000 monthly invoices following the pandemicLONDON, May 23, 2022 - Loughton Contracts has announced that it selected Medius , a leading provider of Accounts Payable automation and wider spend management solutions, to help the company move from a manual, paper-based invoice process, to a digital, paperless system.  Loughton Contracts processes 2,000 to 3,000 invoices every month, with the payment of invoices to suppliers and contractors sitting right at the heart of the business. With

NCC to build a new school for 850 students in Finland

NCC has been commissioned by the city of Mikkeli to build the Saimaanportti school in Finland. The project is a turnkey contract, and the order value is approximately SEK 270 million. The school encompasses approximately 62,000 square meters and will accommodate 850 students from grades 1 through 9. NCC’s assignment also includes the construction of a sports hall, gym and schoolyard. The building will be built out of wood and concrete and has been designed to be a supportive and healthy learning environment with many different educational opportunities in the same building. “

BioStock:Targinta takes lead in the ADC field in the Nordics

Targinta has selected the first ADC drug candidate, TARG9, which is armed with a powerful toxin, primarily for the treatment of triple-negative breast cancer and glioblastoma. With this, the company is established as a leading player in the Nordics in the field of so-called antibody-drug conjugates. BioStock dives deep into the potential and benefits of the ADC technology.Read the full article at biostock.se : https://www.biostock.se/en/2022/05/targinta-takes-lead-in-the-adc-field-in-the-nordics/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from Pennsylvania and Maryland Departments of Health making IMMray™ PanCan-d test available in 48 US states

LUND, SWEDEN – The Pennsylvania and Maryland Departments of Health have granted Immunovia, Inc., the US subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), Clinical Laboratory permits, allowing physicians in Pennsylvania and Maryland to order the IMMray™ PanCan-d test for their patients.   “Many clinicians in Pennsylvania and Maryland have been at the forefront of efforts to enhance surveillance for pancreatic cancer. We are very happy that these physicians can now utilize IMMray™ PanCan-d to detect pancreatic cancer in at-risk patients at stages 1 and 2. With these permits, we are

Cantargia publishes interim report for first quarter 2022

Cantargia AB’s (”Cantargia”) interim report for first quarter 2022 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the first quarter · Clinical development of nadunolimab in pancreatic cancer (PDAC) was advanced by including nadunolimab in Pancreatic Cancer Action Network’s (PanCAN) phase II/III clinical trial Precision Promise℠. · The first patient with non-squamous non-small cell lung cancer (NSCLC) was treated in a new arm in CANFOUR, and the first patient with triple-negative breast cancer was treated in the

HODL SPAC Europe AB: Interim report for the first quarter 2022

HODL SPAC Europe AB (publ) hereby publishes the interim report for the period January – March 2022.  The interim report is available as an attached document and on the company's website (www.hodlspac.se). Below is a summary of the report.”Today's market climate clarifies some of the benefits of a listing via a SPAC. Since the listing in January, we have met with a large number of companies that work with blockchain, and there are many companies of good quality."  - Vahid Toosi, CEO First quarter 2022 · Earnings per share amounted to SEK -0.04 (--). · Profit after tax amounted to

The Board of Directors of Haldex AB (publ) withdraws proposal of confirmation of allotment under 2021 LTI

The Board of Directors of Haldex AB (publ) has decided to withdraw the previously communicated proposal to the Annual General Meeting 2022 of confirmation of allotment under the incentive program for the CEO which was approved by the Annual General Meeting 2021 (“2021 LTI”).The 2021 LTI gave the CEO the right to, under certain conditions, acquire Haldex shares against a pre-defined strike price (the “Options”). For participation in the 2021 LTI the CEO was required to own a certain number of shares in Haldex (“Qualifying Shares”). Pursuant to the terms of the 2021 LTI, the CEO were to

Akobo Minerals – First quarter 2022 results

OSLO, 23 May 2022: Akobo Minerals AB (publ) (EURONEXT: AKOBO) today reported its first quarter 2022 results. Akobo Minerals is still in a project development phase and consequently had no income in the first quarter. The net loss for the period was SEK 0.373 million, affected by positive foreign exchange effects. The company has no external debt and a strong cash position of SEK 21 million.   Jørgen Evjen, CEO of Akobo Minerals, said: “The first quarter of 2022 proved to be a very positive start to the year, with many highlights. Our exploration team has been effective in completing

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 20th May 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,845,711 shares.  Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Skarta will be making everyday life effortless and clean also in Pirkanmaa – Skarta was awarded the contract for the building of pumping stations for Tampere Region Central Wastewater Treatment Plant

On 13 May, Skarta signed a contract with Tampere Region Central Wastewater Treatment Plant Ltd for the building of two pumping stations that serve the entirety of the Tampere region and many of its neighbouring municipalities. The contract’s value is approximately EUR 11 million. Skarta begins work on the pumping stations at the turn of May and June and the stations are expected to be operational by the end of 2024.A new wastewater treatment plant that uses the latest treatment technologies is being constructed in Tampere as a joint project between several municipalities. The participating

Baseload Capital Sweden AB Secures €25 Million Debt Facility to Finance Geothermal Projects

Baseload Capital Sweden AB (“Baseload”) is pleased to announce that it has signed a €25 million convertible term facility agreement (the “Facility”) with SDCL Energy Efficiency Income Trust plc (“SEEIT”). The Facility will be used to re-finance Baseload’s operational assets and assets in construction or late-stage development as well as to finance future pipeline projects. The Facility can be utilized during the availability period and has a 10-year tenor after each draw down. The funding is eligible when the bond is redeemed. Alexander Helling, the CEO of Baseload Capital says,

Inhalation Sciences AB (publ) releases Q1 Report 2022

(Stockholm, Sweden, 23 May 2022) Inhalation Sciences AB announces that its first quarter interim report for January 1 – March 31, 2022 is now available on the company’s website. To read the whole report (in Swedish), visit: http://inhalation.se/investors/finansiella-rapporter/Summary of the interim report During the first quarter, ISAB had sales of SEK 2.8 million with revenue of just over SEK 2 million at the end of the period. Although sales are lower than in the same period last year, we also have a large order backlog of over SEK 8 million (SEK 200,000 during the same period last

Asetek SimSports™ Products to be Available in GetSpeed RaceTaxi Shop, Pro-Car Race Team Sponsorship, and More

Aalborg, Denmark – May 23, 2022 – Asetek, sim racing gear innovator, along with GetSpeed, the motorsports performance center at the Nürburgring, announced an agreement whereby Asetek SimSports™ racing products will be available to try out in the GetSpeed RaceTaxi shop, located literally next to the race track. As part of the agreement and as an official sponsor of the GetSpeed Race Team, Asetek SimSports™ branding will be prominent on the factory-supported Mercedes-AMG GT3 Evo GetSpeed racecar, a top contender in the 50th-anniversary edition of the 24-hr Nürburgring  Race, and on race

Hansa Biopharma completes enrollment in imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantation

· 30 patients with active or chronic active antibody mediated rejection (AMR) episodes post kidney transplantation have been enrolled and randomized 2:1 to imlifidase v.s. standard-of-care · Completion of enrollment marks an important milestone for Hansa, as the company explores the potential of imlifidase in the post transplantation setting.  · Acute AMR episodes post kidney transplantation occur in 5-7% of patients, with significant risk of patients losing graft function. There is no approved treatment for preventing and treating AMR.Lund, Sweden May 23, 2022. Hansa Biopharma AB, “

Operations update

EnQuest PLC, 23 May 2022 Operations update Good production performance year to date; full year guidance remains unchanged EnQuest Chief Executive, Amjad Bseisu, said: "EnQuest remains on track to deliver against its 2022 targets. Performance at Kraken has been strong, with the FPSO continuing to operate with top quartile uptime. "Underlining EnQuest's long-term commitment to investing in the North Sea, our largest activity programme since 2014 is well underway. At Magnus, we have successfully restored production to two wells, completed a well intervention which has already

Operational Update

23 May 2022 IOG plc Operational Update IOG plc ("IOG", or "the Company"), (AIM: IOG.L), the Net Zero UK gas and infrastructure operator focused on high return projects, provides a further operational update. Over the past month, Blythe and Elgood hydrocarbon liquids (condensate) flowing into the Saturn Banks Reception Facilities (SBRF) slugcatcher have fluctuated considerably, reaching peak levels of up to 1,850bbl/d. The SBRF, which lies adjacent to the main Perenco Bacton terminal, is co-owned by IOG and CalEnergy Resources Limited and operated by Perenco (UK) Limited (PUK).

There are no items matching the current filter
There are no more items matching the current filter
Back to top